<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the effectiveness of Uncaria tomentosa in minimizing the side effects of chemotherapy and improving the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients, a randomized clinical trial was conducted </plain></SENT>
<SENT sid="1" pm="."><plain>Patients (43) undergoing adjuvant/palliative chemotherapy with <z:chebi fb="0" ids="46345">5-Fluorouracil</z:chebi>/leucovorin + <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX4) were split into two groups: the UT group received chemotherapy plus 300 mg of Uncaria tomentosa daily and the C group received only FOLFOX4 and served as a control </plain></SENT>
<SENT sid="2" pm="."><plain>Blood samples were collected before each of the 6 cycles of chemotherapy, and hemograms, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, enzymes <z:chebi fb="11" ids="22586">antioxidants</z:chebi>, immunologic parameters, and adverse events were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>The use of 300 mg of Uncaria tomentosa daily during 6 cycles of FOLFOX4 did not change the analyzed parameters, and no toxic effects were observed </plain></SENT>
</text></document>